Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: The Princess Margaret IMPACT/COMPACT trial

Genome Medicine

Volumn 8, Issue 1, 2016, Pages

  Stockley, Tracy L ^a,b,c   Oza, Amit M ^b,c   Berman, Hal K ^a,b   Leighl, Natasha B ^b,c   Knox, Jennifer J ^b,c   Shepherd, Frances A ^b,c   Chen, Eric X ^b,c   Krzyzanowska, Monika K ^b,c   Dhani, Neesha ^b,c   Joshua, Anthony M ^b,c   Tsao, Ming Sound ^a,b   Serra, Stefano ^a,b   Clarke, Blaise ^a,b   Roehrl, Michael H ^a,b   Zhang, Tong ^a   Sukhai, Mahadeo A ^a   Califaretti, Nadia ^d,e   Trinkaus, Mateya ^f   Shaw, Patricia ^a,b   van der Kwast, Theodorus ^a,b   Wang, Lisa ^c   Virtanen, Carl ^c   Kim, Raymond H ^b,c   Razak, Albiruni R A ^b,c   Hansen, Aaron R ^b,c   Yu, Celeste ^c   Pugh, Trevor J ^b,c   Kamel Reid, Suzanne ^a,b,c   Siu, Lillian L ^b,c   Bedard, Philippe L ^b,c   more..

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d Grand River Regional Cancer Centre   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f MARKHAM STOUFFVILLE HOSPITAL   (Canada)

Author keywords

Clinical trials; DNA sequencing; Molecular profiling; Precision medicine; Solid tumors

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GENETICS; CANCER PATIENT; CANCER TISSUE; CLASSIFICATION; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DNA DETERMINATION; DNA MODIFICATION; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; FUNCTIONAL STATUS; GENDER; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; ONCOLOGIST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOLID TUMOR; SOMATIC MUTATION; TREATMENT RESPONSE; ADOLESCENT; CANADA; CHEMISTRY; CLINICAL TRIAL; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; IMMUNOHISTOCHEMISTRY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUTATION; NEOPLASMS; PATHOLOGY; PROCEDURES; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; VERY ELDERLY; YOUNG ADULT;

DNA; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CANADA; DNA, NEOPLASM; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASMS; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; YOUNG ADULT;

EID: 84992411227     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/s13073-016-0364-2     Document Type: Article

References (28)

1. Meric-Bernstam F, Brusco L, Shaw K, Horombe C, Kopetz S, Davies MA, et al. Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. J Clin Oncol. 2015;33:2753-62.
2. Lacombe D, Tejpar S, Salgado R, Cardoso F, Golfinopoulos V, Aust D, et al. European perspective for effective cancer drug development. Nat Rev Clin Oncol. 2014;11(8):492-8.
3. Hyman DM, Solit DB. Tumor genetic screening programs: a call to action. J Clin Oncol. 2015;33(25):2725-6.
4. Sukhai MA, Craddock KJ, Thomas M, Hansen AR, Zhang T, Siu L, et al. A classification system for clinical relevance of somatic variants identified in molecular profiling of cancer. Genet Med. 2016;18:128-36.
5. Yanagawa N, Leduc C, Kohler D, Saieg MA, John T, Sykes J, et al. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. J Thorac Oncol. 2012;7(10):1513-21.
6. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-47.
7. Touloumis A, Agresti A, Kateri M. GEE for multinomial responses using a local odds ratios parameterization. Biometrics. 2013;69(3):633-40.
8. Borgan, Ø. (2001), Modeling Survival Data: Extending the Cox Model. Terry M. Therneau and Patricia M. Grambsch, Springer-Verlag, New York, 2000. doi: 10.1002/sim.956.
9. Miller FA, Hayeems RZ, Bytautas JP, Bedard PL, Ernst S, Hirte H, et al. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. Eur J Hum Genet. 2014;22(3):391-5.
10. Blanchette PS, Spreafico A, Miller FA, Chan K, Bytautas J, Kang S, et al. Genomic testing in cancer: Patient knowledge, attitudes, and expectations. Cancer. 2014;120(19):3066-73.
11. André F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol. 2014;15(3):267-74.
12. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. In: Seminars in oncology: 2014. Elsevier; 2014: p. 297-299.
13. Le Tourneau C, Delord J-P, Gonçalves A, Gavoille C, Dubot C, Isambert N, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16:1324-34.
14. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877-83.
15. Laskin J, Jones S, Aparicio S, Chia S, Ch'ng C, Deyell R, et al. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Mol Case Stud. 2015;1(1):a000570.
16. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014;20(6):682-8.
17. Cheng DT, Mitchell TN, Zehir A, Shah RH, Benayed R, Syed A, et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. J Mol Diagn. 2015;17(3):251-64.
18. Von Hoff D, Stephenson Jr J, Rosen P, Loesch D, Borad M, Anthony S, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(33):4877.
19. Tsimberidou A-M, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, et al. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012;18(22):6373-83.
20. Wheler JJ, Janku F, Naing A, Li Y, Stephen B, Zinner RG, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 2016;76:3690-701.
21. Schwaederle M, Parker BA, Schwab RB, Daniels GA, Piccioni DE, Kesari S, et al. Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience. Mol Cancer Ther. 2016;15(4):743-52.
22. Herbst RS, Gandara DR, Hirsch FR, Redman MW, LeBlanc M, Mack PC, et al. Lung Master Protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res. 2015;21(7):1514-24.
23. Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016. DOI: 10.1001/jamaoncol.2016.2129.
24. Mody RJ, Wu Y-M, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA. 2015;314(9):913-25.
25. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu Y-M, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3(111):111ra121.
26. Rodon J, Soria J, Berger R, Batist G, Tsimberidou A, Bresson C, et al. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial. Ann Oncol. 2015;26:1791-8.
27. Sleijfer S, Bogaerts J, Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013;31(15):1834-41.
28. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-92.